Back to top
more

Jazz Pharmaceuticals (JAZZ)

(Delayed Data from NSDQ)

$111.22 USD

111.22
742,114

+1.76 (1.61%)

Updated Apr 29, 2024 04:00 PM ET

After-Market: $111.23 +0.01 (0.01%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value B Growth D Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (91 out of 252)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Nektar (NKTR) Stock Surges 75% in a Week: Here's Why

by Zacks Equity Research

Nektar's (NKTR) shares rally almost 75% in a week on corrected efficacy data for rezpeg studies, earlier miscalculated by Eli Lilly.

Immunovant (IMVT) Q1 Loss Wider Y/Y, Pipeline in Focus

by Zacks Equity Research

Immunovant's (IMVT) reports wider-than-expected loss for fiscal first-quarter 2023. IMVT is on track with the pipeline developments.

Jazz (JAZZ) Beats on Q2 Earnings & Sales, Raises '23 View

by Zacks Equity Research

Jazz (JAZZ) reports better-than-expected second-quarter results as earnings and sales beat expectations. The company raises its financial guidance for 2023.

Wall Street Analysts See a 51.66% Upside in Jazz (JAZZ): Can the Stock Really Move This High?

by Zacks Equity Research

The consensus price target hints at a 51.7% upside potential for Jazz (JAZZ). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Jazz (JAZZ) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates

by Zacks Equity Research

While the top- and bottom-line numbers for Jazz (JAZZ) give a sense of how the business performed in the quarter ended June 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Jazz Pharmaceuticals (JAZZ) Q2 Earnings and Revenues Top Estimates

by Zacks Equity Research

Jazz (JAZZ) delivered earnings and revenue surprises of 1.12% and 0.51%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Ligand (LGND) Up 4% on Raised '23 EPS, Beats on Q2 Earnings

by Zacks Equity Research

Ligand Pharmaceuticals (LGND) reports second-quarter results as earnings beat the estimates, but sales miss the mark. Management raises the 2023 financial outlook.

Nektar Therapeutics (NKTR) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

Nektar (NKTR) delivered earnings and revenue surprises of 10% and 2.13%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Is a Surprise Coming for Jazz Pharmaceuticals (JAZZ) This Earnings Season?

by Zacks Equity Research

Jazz Pharmaceuticals (JAZZ) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Axsome (AXSM) Q2 Earnings Beat, Stock Dips on Pipeline Updates

by Zacks Equity Research

Axsome (AXSM) incurs a narrower-than-expected loss in the second quarter. The company provides updates on its central nervous system candidates.

Acutus Medical, Inc. (AFIB) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Acutus Medical, Inc. (AFIB) delivered earnings and revenue surprises of -3.28% and 14.98%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Will High Medical Costs Hurt Cigna (CI) in Q2 Earnings?

by Zacks Equity Research

Cigna's (CI) Q2 results are likely to reflect strength in the specialty pharmacy business and growing medical customer base, partly offset by higher medical expenses.

Neurocrine Biosciences (NBIX) Q2 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Neurocrine (NBIX) delivered earnings and revenue surprises of 23.38% and 0.98%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

The Zacks Analyst Blog Highlights Jazz Pharmaceuticals, Oshkosh and StoneCo

by Zacks Equity Research

Jazz Pharmaceuticals, Oshkosh and StoneCo are part of the Zacks top Analyst Blog.

Sejuti Banerjea headshot

3 Stocks to Buy as Recession Looks Unlikely

by Sejuti Banerjea

These are opportunities to buy at reasonable valuations.

Jazz Pharmaceuticals (JAZZ) to Report Q2 Results: Wall Street Expects Earnings Growth

by Zacks Equity Research

Jazz (JAZZ) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will Growing Customer Base Aid Centene (CNC) in Q2 Earnings?

by Zacks Equity Research

Centene's (CNC) Q2 results are likely to reflect growing Medicaid and Marketplace membership, coupled with an improved HBR, partly offset by escalating medical expenses.

What's in the Cards for Universal Health (UHS) in Q2 Earnings?

by Zacks Equity Research

Universal Health's (UHS) Q2 results are likely to benefit from higher patient volumes at its acute care hospitals and behavioral health facilities, partly offset by increased physician expenses.

Will High Medical Costs Hurt Molina Healthcare's (MOH) Q2 Earnings?

by Zacks Equity Research

Molina Healthcare's (MOH) Q2 results are likely to reflect the membership growth in its Medicaid and Medicare business units, partly offset by an elevated medical cost level.

Will High Tech Costs Hurt Teladoc Health (TDOC) in Q2 Earnings?

by Zacks Equity Research

Teladoc Health's (TDOC) Q2 results are likely to have benefited from improved access fees and growing BetterHelp membership, partly offset by elevated technology and development expenses.

Elevance Health (ELV) Beats on Q2 Earnings, Ups '23 Profit View

by Zacks Equity Research

Elevance Health's (ELV) Q2 results benefit from an expanding customer base and solid pharmacy product revenues. Adjusted net income is expected to be more than $32.85 per share for 2023.

Wall Street Analysts Think Jazz (JAZZ) Could Surge 54.74%: Read This Before Placing a Bet

by Zacks Equity Research

The mean of analysts' price targets for Jazz (JAZZ) points to a 54.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Is SPDR S&P Pharmaceuticals ETF (XPH) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for XPH

Rimmi Singhi headshot

Uncover Value Opportunities With These 5 Earnings Yield Gems

by Rimmi Singhi

Unlock hidden value and drive higher returns to your portfolio with high earnings yield stocks like PLAY, URBN, KELYA, LTHM and JAZZ.

JAZZ vs. ZTS: Which Stock Is the Better Value Option?

by Zacks Equity Research

JAZZ vs. ZTS: Which Stock Is the Better Value Option?